People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

( MENAFN - EIN Presswire) Spravato® (esketamine) has been approved for use as a standalone treatment for depression, without the requirement of an accompanying antidepressant. Legal Disclaimer: ...

Johnson & Johnson (NYSE:JNJ) announced Tuesday that the U.S. FDA approved a supplemental New Drug Application for its depression therapy Spravato (esketamine), expanding its use as a single agent ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known target in depression. Since its initial approval in 2019, Spravato has ...